CDC-RFA-PS23-2302: Accelerating the Prevention and Control of HIV, Viral Hepatitis, STDs, and TB in the U.S. Affiliated Pacific Islands
Closed
This grant is closed. A newer notice from the same program is forecast: Strengthening Collaboration Between Tuberculosis Control Programs and Affiliated Partners in the United States. (CDC-RFA-PS-27-0053). Status: Expected deadline May 21, 2027. It is in our archive of Centers for Disease Control - NCHHSTP notices from 2022.
Centers for Disease Control - NCHHSTP offered grants to any type of organization. It expected to make about 6 awards worth $19.5 million in total. Applications closed on July 31, 2022.
From the official notice on Grants.gov, last changed May 24, 2022. Checked November 7, 2026.
- Total funding$19.5 million
- Expected awards6
- Cost sharingNot required
- Funding typeCooperative Agreement
Key dates
| Posted | May 24, 2022 |
|---|---|
| Deadline | July 31, 2022 |
| Archived by Grants.gov | August 30, 2022 |
Who can apply
This opportunity was open to any type of organization.
All 16 applicant types the notice lists
- State governments
- County governments
- City or township governments
- Special district governments
- Independent school districts
- Public and State controlled institutions of higher education
- Native American tribal governments (Federally recognized)
- Public housing authorities/Indian housing authorities
- Native American tribal organizations (other than Federally recognized tribal governments)
- Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
- Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
- Private institutions of higher education
- For profit organizations other than small businesses
- Small businesses
- Others (see text field entitled "Additional Information on Eligibility" for clarification)
- Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled "Additional Information on Eligibility"
(1) Foreign Institutions Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. (2) Applicant must provide proof of ability to serve populations in one of the jurisdictions listed below: (A) Commonwealth of the Northern Mariana Islands (CNMI) (B) American Samoa (C) Guam (D) Federated States of Micronesia (FSM) (E) Republic of the Marshall Islands (RMI) (F) Republic of Palau Evidence of ability may include documentation that applicant is a territorial government or a bona fide agent in the Commonwealth of the Northern Mariana Islands, American Samoa, Guam, the Federated States of Micronesia, the Republic of the Marshall Islands, or the Republic of Palau. Documentation must be provided in attachment labeled EvidenceofAbility. A bona fide agent is an agency/organization identified by the state as eligible to submit an application under the state eligibility in lieu of a state application. If applying as a bona fide agent of a state or local government, a legal, binding agreement from the state or local government as documentation of the status is required. Attach with “Other Attachment Forms” when submitting via www.grants.gov If applicant is other than a Department/Ministry of Health in the specified jurisdiction, the applicant must submit a memorandum of agreement/memorandum of understanding with the Department/Ministry of Health in the jurisdiction for which it is applying. The memorandum of agreement/memorandum of understanding should include the authority to collect and submit surveillance data. Documentation must be provided in attachment labeled MOUwith(insert name of Department/Ministry of Health). Attach with "Other Attachment Forms" when submitting via www.grants.gov. Applications that do not comply with these requirements will be determined non-responsive and will not receive further review.
Is this a realistic fit?
- Most of the program's money (96% over five years) went to state and local governments.
- No cost sharing or match is required.
What the grant funds
The U.S. Affiliated Pacific Islands (USAPI) are comprised of the three U.S. territories of American Samoa, the Commonwealth of the Northern Mariana Islands, and Guam, as well as the three sovereign nations of the Federated States of Micronesia, the Republic of the Marshall Islands, and the Republic of Palau. The public health care systems in these remote islands require assistance to improve the infrastructure, capacity, and local expertise to prevent HIV in high-risk populations and to effectively address the high burden of sexually transmitted diseases (STDs), tuberculosis (TB), and viral hepatitis (VH) in their jurisdictions. Additionally, laboratory capacity is limited, surveillance systems are fragmented, and provision of health care is challenging and costly due to the vast geographic distances and broadly dispersed population throughout islands across the Pacific Ocean. This integrated Notice of Funding Opportunity (NOFO) is supported by the National Center for HIV, Viral Hepatitis, STD, and TB Prevention (NCHHSTP) and aims to: Promote program collaboration and services integration to capitalize on the opportunity to prevent , diagnose, and treat HIV, STD, TB, and VH. Improve collection, sharing, reporting, analysis, interpretation, and use of surveillance and other program data. Assure implementation of policies and plans that will make effective use of resources to improve health outcomes. Develop the public health care workforce through training and education. Improve public health laboratory capacity. Enhance prevention, care, follow-up and treatment for disease-specific activities. Reduce administrative burdens of managing multiple cooperative agreements by consolidating the application and award process as well as streamlining the reporting requirements.
Who has won Project Grants and Cooperative Agreements for Tuberculosis Control Programs grants before
From fiscal 2021 to 2025, Project Grants and Cooperative Agreements for Tuberculosis Control Programs (93.116) awarded $416 million across 153 grant awards, an average of $2.7 million per award.
| Recipient | State | Awards | Amount |
|---|---|---|---|
| California Department of Public Health | California | 3 | $44.3 million |
| Department of State Health Services | Texas | 2 | $35.0 million |
| Florida Department of Health | Florida | 4 | $25.2 million |
| City of New York | New York | 2 | $24.4 million |
| County of Los Angeles | California | 2 | $20.4 million |
Applying now
This notice no longer takes applications. Apply under the newer notice, CDC-RFA-PS-27-0053, which is forecast.
The notice on Grants.gov keeps its full text and attachments, which is useful for planning a resubmission.
Questions people ask
Is CDC-RFA-PS23-2302 still open?
No. It closed on July 31, 2022. A newer notice is forecast: CDC-RFA-PS-27-0053, expected deadline May 21, 2027.
Who can apply for Accelerating the Prevention and Control of HIV, Viral Hepatitis, STDs, and TB in the U.S. Affiliated Pacific Islands?
Centers for Disease Control - NCHHSTP accepted applications from any type of organization. The notice adds further conditions, so read its eligibility section.
What is the deadline for Accelerating the Prevention and Control of HIV, Viral Hepatitis, STDs, and TB in the U.S. Affiliated Pacific Islands?
Closed July 31, 2022. Applications are no longer accepted; the program's newer notices are on this page when there are any.
How much funding is available?
About $19.5 million in total across about 6 awards.
Who has won Project Grants and Cooperative Agreements for Tuberculosis Control Programs grants before?
The largest recipients over five fiscal years were California Department of Public Health, Department of State Health Services, Florida Department of Health. The program made 153 awards worth $416 million in that time.
Similar open grants
- Single Source for the Continuation of the Caring for OutPatiEnts after Acute Kidney Injury (COPE-AKI) Scientific and Data Research Center (U01 Clinical Trial Required)
- Single Source for the Continuation of the Epidemiology of Diabetes Interventions and Complications (EDIC) Study Research Center (Collaborative U01 Clinical Trial Not Allowed)
- Data Coordinating Center for the Aging and Alzheimer’s Disease Mouse Brain Atlas (AD-MBA) (U24 Clinical Trial Not Allowed)
- Amyotrophic Lateral Sclerosis (ALS) Intermediate Patient Population Expanded Access (U01 Clinical Trial Required)
- Advanced Development and Validation of Emerging Technologies for Basic and Clinical Cancer Research (R33 Clinical Trial Not Allowed)
- Early-Stage Innovative Technology Development for Basic and Clinical Cancer Research (R61 Clinical Trial Not Allowed)